Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

Cardiovascular Diabetology

Volumn 20, Issue 1, 2021, Pages

  Xiang, Boyang ^a   Zhao, Xiaoya ^a   Zhou, Xiang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cardiovascular benefits; Diabetes; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; BIOLOGICAL MARKER;

ARTERIAL STIFFNESS; BLOOD PRESSURE; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DIURESIS; DRUG EFFICACY; DRUG MECHANISM; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; ANIMAL; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY; RISK ASSESSMENT;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLYCEMIC CONTROL; HEART DISEASE RISK FACTORS; HUMANS; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85103995114     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-021-01266-x     Document Type: Review

References (152)

1. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875–83. DOI: 10.1053/j.ajkd.2008.12.031
2. Crane RK. The restrictions on possible mechanisms of intestinal transport of sugars. Membrane Transport and Metabolism. In: Proceedings of a symposium held in Prague, August 22–27, 1960. 1961. pp 439–449.
3. Wright EM, Loo DD, Hirayama BA, Turk E. Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda). 2004;19:370–6.
4. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199–204. DOI: 10.2337/db12-0052
5. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272–7. DOI: 10.1038/ki.2009.87
6. Himsworth HP. The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose. Biochem J. 1931;25(4):1128–46. DOI: 10.1042/bj0251128
7. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94. DOI: 10.1152/physrev.00055.2009
8. Rieg T, Masuda T, Gerasimova M, Mayoux E, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306(2):F188–93. DOI: 10.1152/ajprenal.00518.2013
9. List JF, Woo V, Morales E, Tang W, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–7. DOI: 10.2337/dc08-1863
10. Komoroski B, Vachharajani N, Feng Y, Li L, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–9. DOI: 10.1038/clpt.2008.250
11. Holman RR, Paul SK, Bethel MA, Matthews DR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. DOI: 10.1056/NEJMoa0806470
12. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206. DOI: 10.1056/NEJMoa1414266
13. Inzucchi SE, Zinman B, Fitchett D, Wanner C, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–63. DOI: 10.2337/dc17-1096
14. Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904–7. DOI: 10.1161/CIRCULATIONAHA.118.035759
15. Packer M, Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. DOI: 10.1056/NEJMoa2022190
16. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. DOI: 10.1056/NEJMoa1911303
17. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. DOI: 10.1056/NEJMoa2024816
18. Zinman B, Wanner C, Lachin JM, Fitchett D, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. DOI: 10.1056/NEJMoa1504720
19. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. DOI: 10.1056/NEJMoa1611925
20. Perkovic V, Jardine MJ, Neal B, Bompoint S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. DOI: 10.1056/NEJMoa1811744
21. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation. 2020;141(5):407–10. DOI: 10.1161/CIRCULATIONAHA.119.044359
22. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. DOI: 10.1056/NEJMoa1812389
23. Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2020. 10.1002/ejhf.2073. DOI: 10.1002/ejhf.2073
24. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35. DOI: 10.1056/NEJMoa2004967
25. Bhatt DL, Szarek M, Steg PG, Cannon CP, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28. DOI: 10.1056/NEJMoa2030183
26. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):984–93. DOI: 10.1111/dom.12307
27. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74. DOI: 10.7326/0003-4819-159-4-201308200-00007
28. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265–75. DOI: 10.1111/jdi.12214
29. Yamada T, Shojima N, Noma H, Yamauchi T, et al. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(7):1755–61. DOI: 10.1111/dom.13260
30. El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;137:83–92. DOI: 10.1016/j.diabres.2018.01.004
31. Barnett AH, Mithal A, Manassie J, Jones R, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–84. DOI: 10.1016/S2213-8587(13)70208-0
32. Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21(Suppl 2):34–42. DOI: 10.1111/dom.13611
33. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34(7):1707–26. DOI: 10.1007/s12325-017-0573-0
34. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids. 2003;25(3–4):275–81. DOI: 10.1007/s00726-003-0017-9
35. Brett J, Schmidt AM, Yan SD, Zou YS, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143(6):1699–712.
36. Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Amino Acids. 2017;49(9):1535–41. DOI: 10.1007/s00726-017-2464-8
37. Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90–102. DOI: 10.4330/wjc.v4.i4.90
38. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004;64(5):459–70. DOI: 10.2165/00003495-200464050-00001
39. Corman B, Duriez M, Poitevin P, Heudes D, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA. 1998;95(3):1301–6. DOI: 10.1073/pnas.95.3.1301
40. Candido R, Forbes JM, Thomas MC, Thallas V, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785–92. DOI: 10.1161/01.RES.0000065620.39919.20
41. Yan SD, Schmidt AM, Anderson GM, Zhang J, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269(13):9889–97. DOI: 10.1016/S0021-9258(17)36966-1
42. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582–92. DOI: 10.1016/j.cardiores.2004.05.001
43. Ojima A, Matsui T, Nishino Y, Nakamura N, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47(9):686–92. DOI: 10.1055/s-0034-1395609
44. Oelze M, Kröller-Schön S, Welschof P, Jansen T, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394. DOI: 10.1371/journal.pone.0112394
45. Habibi J, Aroor AR, Sowers JR, Jia G, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9. DOI: 10.1186/s12933-016-0489-z
46. Silva Dos Santos D, Polidoro JZ, Borges-Júnior FA, Girardi ACC. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020;318(2):328–36. DOI: 10.1152/ajpcell.00275.2019
47. Schneider MP, Raff U, Kopp C, Scheppach JB, et al. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol. 2017;28(6):1867–76. DOI: 10.1681/ASN.2016060662
48. Kopp C, Linz P, Maier C, Wabel P, et al. Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging. Kidney Int. 2018;93(5):1191–7. DOI: 10.1016/j.kint.2017.11.021
49. Karg MV, Bosch A, Kannenkeril D, Striepe K, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1):5. DOI: 10.1186/s12933-017-0654-z
50. Tanaka H, Takano K, Iijima H, Kubo H, et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther. 2017;34(2):436–51. DOI: 10.1007/s12325-016-0457-8
51. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62. DOI: 10.1111/dom.12127
52. Masuda T, Muto S, Fukuda K, Watanabe M, et al. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):e14360. DOI: 10.14814/phy2.14360
53. Sarzani R, Giulietti F, Di Pentima C, Spannella F. Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events. Nutr Metab Cardiovasc Dis. 2020;30(10):1622–32. DOI: 10.1016/j.numecd.2020.05.030
54. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479–87. DOI: 10.1111/dom.13126
55. Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693–700. DOI: 10.2337/dc18-2207
56. Baker WL, Buckley LF, Kelly MS, Bucheit JD, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5):e005686.
57. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007. DOI: 10.1161/JAHA.116.004007
58. Wan N, Rahman A, Hitomi H, Nishiyama A. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne). 2018;9:421. DOI: 10.3389/fendo.2018.00421
59. Jones B. Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD? Nat Rev Nephrol. 2014;10(4):181. DOI: 10.1038/nrneph.2014.20
60. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71. DOI: 10.1038/ki.2013.356
61. Storgaard H, Gluud LL, Bennett C, Grøndahl MF, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2016;11(11):e0166125. DOI: 10.1371/journal.pone.0166125
62. Chilton R, Tikkanen I, Cannon CP, Crowe S, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180–93. DOI: 10.1111/dom.12572
63. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–27. DOI: 10.1016/j.jacc.2009.10.061
64. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303. DOI: 10.1007/s10741-015-9471-1
65. Safar ME. Arterial stiffness as a risk factor for clinical hypertension. Nat Rev Cardiol. 2018;15(2):97–105. DOI: 10.1038/nrcardio.2017.155
66. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, et al. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455–69. DOI: 10.1016/j.jacc.2011.11.082
67. Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, et al. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175–81. DOI: 10.1093/eurheartj/eht351
68. Striepe K, Jumar A, Ott C, Karg MV, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167–9. DOI: 10.1161/CIRCULATIONAHA.117.029529
69. Ott C, Jumar A, Striepe K, Friedrich S, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26. DOI: 10.1186/s12933-017-0510-1
70. Solini A, Giannini L, Seghieri M, Vitolo E, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138. DOI: 10.1186/s12933-017-0621-8
71. Tanaka A, Shimabukuro M, Machii N, Teragawa H, et al. Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled Double-Blind EMBLEM Trial. Diabetes Care. 2019;42(10):e159–61. DOI: 10.2337/dc19-1177
72. Tanaka A, Murohara T, Taguchi I, Eguchi K, et al. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016;15(1):133. DOI: 10.1186/s12933-016-0449-7
73. Johnston R, Uthman O, Cummins E, Clar C, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017;21(2):1–218. DOI: 10.3310/hta21020
74. Bolinder J, Ljunggren O, Kullberg J, Johansson L, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. DOI: 10.1210/jc.2011-2260
75. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159–69. DOI: 10.1111/dom.12189
76. Cefalu WT, Leiter LA, Yoon KH, Arias P, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–50. DOI: 10.1016/S0140-6736(13)60683-2
77. Xu L, Nagata N, Nagashimada M, Fen ZG, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–49. DOI: 10.1016/j.ebiom.2017.05.028
78. Schork A, Saynisch J, Vosseler A, Jaghutriz BA, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019;18(1):46. DOI: 10.1186/s12933-019-0852-y
79. Blonde L, Stenlöf K, Fung A, Xie J, et al. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371–80. DOI: 10.1080/00325481.2016.1169894
80. Neeland IJ, McGuire DK, Chilton R, Crowe S, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–26. DOI: 10.1177/1479164115616901
81. Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, et al. Comparison of adipose distribution indices with gold standard body composition assessments in the EMPA-REG H2H SU trial: a body composition sub-study. Diabetes Ther. 2015;6(4):635–42. DOI: 10.1007/s13300-015-0146-7
82. Inoue H, Morino K, Ugi S, Tanaka-Mizuno S, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019;10(4):1012–21. DOI: 10.1111/jdi.12985
83. Schwaiger E, Burghart L, Signorini L, Ristl R, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant. 2019;19(3):907–19. DOI: 10.1111/ajt.15223
84. Ferrannini G, Hach T, Crowe S, Sanghvi A, et al. Energy Balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–5. DOI: 10.2337/dc15-0355
85. Rajeev SP, Cuthbertson DJ, Wilding JPH. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18(2):125–34. DOI: 10.1111/dom.12578
86. Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630–41. DOI: 10.1111/obr.12755
87. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89(3):524–6. DOI: 10.1016/j.kint.2015.12.038
88. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–5. DOI: 10.2337/db15-1356
89. Bouchi R, Terashima M, Sasahara Y, Asakawa M, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16(1):32. DOI: 10.1186/s12933-017-0516-8
90. Sato T, Aizawa Y, Yuasa S, Kishi S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. DOI: 10.1186/s12933-017-0658-8
91. Yagi S, Hirata Y, Ise T, Kusunose K, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:78. DOI: 10.1186/s13098-017-0275-4
92. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71(20):2360–72. DOI: 10.1016/j.jacc.2018.03.509
93. Gori M, Senni M, Gupta DK, Charytan DM, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3442–51. DOI: 10.1093/eurheartj/ehu254
94. Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929–44. DOI: 10.1161/CIRCULATIONAHA.117.028814
95. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “Thrifty Substrate” hypothesis. Diabetes Care. 2016;39(7):1108–14. DOI: 10.2337/dc16-0330
96. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–22. DOI: 10.2337/dc16-0542
97. Ferrannini E, Santoro D, Bonadonna R, Natali A, et al. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol. 1993;264(2 Pt 1):E308–15.
98. Ferrannini E, Muscelli E, Frascerra S, Baldi S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. DOI: 10.1172/JCI72227
99. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931–44. DOI: 10.1016/j.jacc.2019.01.056
100. Testani JM, Chen J, McCauley BD, Kimmel SE, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–72. DOI: 10.1161/CIRCULATIONAHA.109.933275
101. Youm YH, Nguyen KY, Grant RW, Goldberg EL, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–9. DOI: 10.1038/nm.3804
102. Yamanashi T, Iwata M, Kamiya N, Tsunetomi K, et al. Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep. 2017;7(1):7677. DOI: 10.1038/s41598-017-08055-1
103. Shimazu T, Hirschey MD, Newman J, He W, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211–4. DOI: 10.1126/science.1227166
104. Rahman M, Muhammad S, Khan MA, Chen H, et al. The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944. DOI: 10.1038/ncomms4944
105. Nishimura R, Tanaka Y, Koiwai K, Inoue K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11. DOI: 10.1186/s12933-014-0169-9
106. Yokoyama H, Gunasegaram S, Harding SE, Avkiran M. Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol. 2000;36(2):534–40. DOI: 10.1016/S0735-1097(00)00730-0
107. Hui Y, Junzhu C, Jianhua Z. Gap junction and Na+-H+ exchanger alternations in fibrillating and failing atrium. Int J Cardiol. 2008;128(1):147–9. DOI: 10.1016/j.ijcard.2007.06.070
108. Baartscheer A, Schumacher CA, Wust RCI, Fiolet JWT, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73. DOI: 10.1007/s00125-016-4134-x
109. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722–6. DOI: 10.1007/s00125-017-4509-7
110. Baartscheer A, Hardziyenka M, Schumacher CA, Belterman CN, et al. Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol. 2008;154(6):1266–75. DOI: 10.1038/bjp.2008.189
111. Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, et al. Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res. 2005;65(1):83–92. DOI: 10.1016/j.cardiores.2004.09.024
112. Liu T, Takimoto E, Dimaano VL, DeMazumder D, et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res. 2014;115(1):44–54. DOI: 10.1161/CIRCRESAHA.115.303062
113. Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114(1):12–8. DOI: 10.1093/cvr/cvx149
114. Chino Y, Samukawa Y, Sakai S, Nakai Y, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404. DOI: 10.1002/bdd.1909
115. Lytvyn Y, Škrtić M, Yang GK, Yip PM, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77-83. DOI: 10.1152/ajprenal.00555.2014
116. Zhao Y, Xu L, Tian D, Xia P, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–62. DOI: 10.1111/dom.13101
117. Kırça M, Oğuz N, Çetin A, Uzuner F, et al. Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. J Recept Signal Transduct Res. 2017;37(2):167–73. DOI: 10.1080/10799893.2016.1203941
118. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608–19. DOI: 10.1080/15257770802138558
119. Gersch C, Palii SP, Kim KM, Angerhofer A, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008;27(8):967–78. DOI: 10.1080/15257770802257952
120. Corry DB, Eslami P, Yamamoto K, Nyby MD, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75. DOI: 10.1097/HJH.0b013e3282f240bf
121. Gasse P, Riteau N, Charron S, Girre S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009;179(10):903–13. DOI: 10.1164/rccm.200808-1274OC
122. Çağlı K, Turak O, Canpolat U, Özcan F, et al. Association of serum uric acid level with blood pressure variability in newly diagnosed essential hypertension. J Clin Hypertens (Greenwich). 2015;17(12):929–35. DOI: 10.1111/jch.12641
123. Mantovani A, Rigolon R, Pichiri I, Pernigo M, et al. Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. J Endocrinol Invest. 2016;39(2):159–67. DOI: 10.1007/s40618-015-0354-z
124. Huang H, Huang B, Li Y, Huang Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24. DOI: 10.1093/eurjhf/hft132
125. Di Franco A, Cantini G, Tani A, Coppini R, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol. 2017;243:86–90. DOI: 10.1016/j.ijcard.2017.05.032
126. Li C, Zhang J, Xue M, Li X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. DOI: 10.1186/s12933-019-0816-2
127. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biol Med. 2017;104:298–310. DOI: 10.1016/j.freeradbiomed.2017.01.035
128. Verma S, Mazer CD, Yan AT, Mason T, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140(21):1693–702. DOI: 10.1161/CIRCULATIONAHA.119.042375
129. Sezai A, Sekino H, Unosawa S, Taoka M, et al. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol. 2019;18(1):76. DOI: 10.1186/s12933-019-0877-2
130. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132. DOI: 10.1186/s12933-018-0775-z
131. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–25.
132. Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017;24(5):443–51. DOI: 10.5551/jat.RV17001
133. Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF,Harris D. Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. J Nat Sci. 2017;3(4).
134. Matsumura M, Nakatani Y, Tanka S, Aoki C, et al. Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM). Diabetes Ther. 2017;8(4):821–7. DOI: 10.1007/s13300-017-0274-3
135. Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–7. DOI: 10.1016/j.metabol.2018.02.002
136. Hattori S. Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance. J Diabetes Investig. 2018;9(4):870–4. DOI: 10.1111/jdi.12781
137. Tan SA, Tan L. Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-gamma, tumor necrosis factor-alpha, interleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus. J Am Coll Cardiol. 2018;71(11):1830–1830. DOI: 10.1016/S0735-1097(18)32371-4
138. Prattichizzo F, De Nigris V, Micheloni S, La Sala L, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515–22. DOI: 10.1111/dom.13488
139. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44(6):457–64. DOI: 10.1016/j.diabet.2018.09.005
140. Shin SJ, Chung S, Kim SJ, Lee EM, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE. 2016;11(11):e0165703. DOI: 10.1371/journal.pone.0165703
141. Satou R, Cypress MW, Woods TC, Katsurada A, et al. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. Am J Physiol Renal Physiol. 2020;318(1):F67-f75. DOI: 10.1152/ajprenal.00402.2019
142. Avogaro A, Fadini GP, Del Prato S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care. 2020;43(3):501–7. DOI: 10.2337/dc19-1410
143. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508–11. DOI: 10.2337/dci19-0074
144. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–8. DOI: 10.1016/S0140-6736(20)30748-0
145. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014;466(6):1037–53. DOI: 10.1007/s00424-014-1480-8
146. Campbell RT, Jhund PS, Castagno D, Hawkins NM, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012;60(23):2349–56. DOI: 10.1016/j.jacc.2012.04.064
147. Lam CSP, Voors AA, de Boer RA, Solomon SD, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–92. DOI: 10.1093/eurheartj/ehy301
148. Zhang N, Feng B, Ma X, Sun K, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019;18(1):107. DOI: 10.1186/s12933-019-0914-1
149. Pabel S, Wagner S, Bollenberg H, Bengel P, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690–700. DOI: 10.1002/ejhf.1328
150. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. DOI: 10.1007/s40265-014-0337-y
151. Das SR, Everett BM, Birtcher KK, Brown JM, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72(24):3200–23. DOI: 10.1016/j.jacc.2018.09.020
152. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486